BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

...of NLRP3 and STING to treat cancer.An NLRP3...
...GlickPatents: None issuedTARGETScGAS - cGAMP synthaseNLRP3 (NALP3; CIAS1...
BioCentury | Oct 17, 2020
Finance

Novartis Venture Fund’s move to earlier, riskier bets starting to pay off

...most well-characterized component of the protein complex, NLRP3...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...a predictor of heart failure. The inflammasome target NLRP3...
...Publication of Phase I data from the NLRP3...
...factorENPEP – Glutamyl aminopeptidaseMPO – MyeloperoxidaseNLRP3 (NALP3; CIAS1...
BioCentury | Sep 24, 2020
Finance

Data Bytes: record fund for Longitude follows rush of deals, IPOs

...are the two largest European biotech acquisitions so far this year: the €380 million takeout of NLRP3...
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

...developing a preclinical candidate against inflammasome target NLRP3...
...neuroinflammation in a variety of neurodegenerative conditions. NLRP3...
...43SNCA – ɑ synuclein NLRP3 (NALP3; CIAS1) – NLR family pyrin domain containing 3 Selina...
BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...than 50 models of disease (see “NLRP3 Early and Often”).Innate immune and other cells use NLRP3...
...Innate Immunity Targets”) Pharma feeding frenzyThe deal gives Roche two clinical NLRP3 inhibitors: Inzomelid, a brain-penetrant NLRP3...
...see “BMS Expanding I-O Portfolio”).TARGETSNLRP3 (NALP3; CIAS1) – NLR family pyrin domain containing 3 Stephen Hansen Forbion Capital Partners Inflazome Ltd. Ventrus Biosciences Inc. NodThera Ltd. NLR family pyrin domain containing 3 (NLRP3) (NALP3) (CIAS1) inflammasome...
BioCentury | Jun 4, 2020
Finance

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

...operating in an area ripe for takeouts -- the inflammasome. The biotech's lead program targets NLRP3...
...with an NLRP3 inhibitor in Phase I testing. Inflazome Ltd. has two programs, Inzomelid for CIAS1-associated...
...Capital are joining NodThera’s board in connection with the financing. Targets NLRP3 (NALP3; CIAS1) - NLR family pyrin domain containing 3 Stephen...
BioCentury | May 6, 2020
Emerging Company Profile

Ventus: A structural edge in innate immunity targets

...history of investing in innate immune assets. Versant was the founding and sole investor in NLRP3...
...AG (NYSE:NVS; SIX:NOVN). Other companies in the target space include NodThera Ltd., which is targeting NLRP3...
...raised: $60 million Investors: GV, Versant Ventures CEO: Marcelo Bigal Targets NLRP3 (NALP3; CIAS1) - NLR family pyrin domain containing 3 Lauren...
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

...billion in milestones for the IFM Tre subsidiary, which is focused on inhibitors of the NLRP3...
...coming months. Targets cGAS - cGAMP synthase IL-1β - Interleukin 1β NLRP3 (NALP3; CIAS1) - NLR family pyrin domain containing 3...
BioCentury | Jan 28, 2020
Company News

Quenching the flames of inflammatory cell death

...other targets within the gasdermin family. Within the inflammasome space, some companies have begun investigating NLRP3...
...IL-18 - Interleukin-18; NLRC4 - NRL family CARD domain containing 4; NLRP3 (NALP3; CIAS1) - NLR family pyrin domain containing 3...
...family CARD domain containing 4 NLRP3 (NALP3; CIAS1) - NLR family pyrin domain containing 3 Elizabeth S. Eaton, Staff Writer Gasdermin D (GSDMD) NLR family pyrin domain containing 3 (NLRP3) (NALP3) (CIAS1) Inflammasome pyroptosis netosis...
Items per page:
1 - 10 of 199